The name Gossamer Bio depicts the symbolism behind the gossamer thread, the fragile connection that binds all relationships in life. In our context, this is intended to highlight the importance of our relationships with patients in a healthcare system, employees, shareholders, providers and partners. We take these relationships seriously and aim to strengthen these connections continuously. Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to enhance the lives of people living with these rare diseases.
Faheem Hasnain
Co-Founder, Chairman, and Chief Executive Officer
Richard Aranda, M.D.
Chief Medical Officer
Jeff Boerneke
General Counsel and Secretary
Matt Cravets
Senior Vice President, Biometrics
Bryan Giraudo
Chief Operating Officer & Chief Financial Officer
Lisa Nolan, Ph.D.
Managing Director and President, Gossamer Bio Ireland
Caryn Peterson
Executive Vice President, Regulatory Affairs
Bob Smith
Chief Commercial Officer
Christian Waage
Executive Vice President, Technical Operations & Administration
Deanna Weber
Senior Vice President, Human Resources